{"title":"Genmab的DuoBody™技术获得诺华合作验证","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1753","DOIUrl":null,"url":null,"abstract":"Genmab has formed a bispecific antibody collaboration with Novartis that is potentially worth up to US$175 M plus research funding and royalties. In return for US$2 M upfront, Genmab will create panels of bispecific antibodies to two undisclosed disease target combinations selected by Novartis using its DuoBody™ technology. The deal is the latest in a string of partnerships focused on the development of next-generation antibody therapeutics.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"5 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Genmab’s DuoBody™ Technology Gains Validation with Novartis Collaboration\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I6.1753\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Genmab has formed a bispecific antibody collaboration with Novartis that is potentially worth up to US$175 M plus research funding and royalties. In return for US$2 M upfront, Genmab will create panels of bispecific antibodies to two undisclosed disease target combinations selected by Novartis using its DuoBody™ technology. The deal is the latest in a string of partnerships focused on the development of next-generation antibody therapeutics.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"5 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I6.1753\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I6.1753","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Genmab’s DuoBody™ Technology Gains Validation with Novartis Collaboration
Genmab has formed a bispecific antibody collaboration with Novartis that is potentially worth up to US$175 M plus research funding and royalties. In return for US$2 M upfront, Genmab will create panels of bispecific antibodies to two undisclosed disease target combinations selected by Novartis using its DuoBody™ technology. The deal is the latest in a string of partnerships focused on the development of next-generation antibody therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
